Vividion Therapeutics Expands Clinical Development of WRN Inhibitor VVD-214 with Phase 2 Combination Study in First-Line Patients with Advanced Colorectal Cancer

Posted on by sHq_LoGiNz

SAN DIEGO & BERLIN–(BUSINESS WIRE)–Vividion announces first patient dosed in Phase 2 clinical trial of VVD-214, an investigational oral inhibitor of Werner helicase (WRN).

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.